Literature DB >> 12116189

Association of the muscarinic cholinergic 2 receptor (CHRM2) gene with major depression in women.

David E Comings1, Sujihan Wu, M Rostamkhani, Matt McGue, William G Iacono, James P MacMurray.   

Abstract

Cholinergic neurons have been implicated in depression and in the disorders of REM sleep in depression. We examined a common A-> T 1890 polymorphism in the 3' UTR of the cholinergic muscarinic receptor 2 (CHRM2) gene. There was a significant increase in the frequency of 11 homozygotes in 126 women with major depression (43.7%) compared to 304 women without major depression (25.7%), P =.001. There was no increase in the frequency of 11 homozygotes in 52 men with depression (26.9%) compared to 278 men without depression (27.7%). Regression analysis, scoring subjects with the 11 genotype as 1, and those with other genotypes as 0, showed that in women r(2) =.030, F = 13.37, P =.0003. By contrast, in men r(2) =.00001, F = 0.002, P =.96. These results are consistent with a gender-specific role of the CHRM2 gene in depression in women. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12116189     DOI: 10.1002/ajmg.10406

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  37 in total

Review 1.  A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes II: the importance of mRNA secondary structure in assessing the functionality of 3' UTR variants.

Authors:  Jian-Min Chen; Claude Férec; David N Cooper
Journal:  Hum Genet       Date:  2006-06-29       Impact factor: 4.132

Review 2.  Rapid eye movement (REM) sleep: an endophenotype for depression.

Authors:  Sieglinde Modell; Christoph J Lauer
Journal:  Curr Psychiatry Rep       Date:  2007-12       Impact factor: 5.285

3.  Synergistic effects of genetic variation in nicotinic and muscarinic receptors on visual attention but not working memory.

Authors:  P M Greenwood; M-K Lin; R Sundararajan; K J Fryxell; R Parasuraman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-11       Impact factor: 11.205

4.  Genetic predictors of depressive symptoms in cardiac patients.

Authors:  Jeanne M McCaffery; Qing Ling Duan; Nancy Frasure-Smith; Amina Barhdadi; Francois Lespérance; Pierre Théroux; Guy A Rouleau; Marie-Pierre Dubé
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-04-05       Impact factor: 3.568

5.  Elevated Hippocampal Cholinergic Neurostimulating Peptide precursor protein (HCNP-pp) mRNA in the amygdala in major depression.

Authors:  Sabrina Bassi; Marianne L Seney; Pablo Argibay; Etienne Sibille
Journal:  J Psychiatr Res       Date:  2015-02-20       Impact factor: 4.791

6.  Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.

Authors:  Maura L Furey; Wayne C Drevets
Journal:  Arch Gen Psychiatry       Date:  2006-10

Review 7.  G protein-coupled receptors in major psychiatric disorders.

Authors:  Lisa A Catapano; Husseini K Manji
Journal:  Biochim Biophys Acta       Date:  2006-10-03

8.  Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder.

Authors:  D M Cannon; J K Klaver; S K Gandhi; G Solorio; S A Peck; K Erickson; N Akula; J Savitz; W C Eckelman; M L Furey; B J Sahakian; F J McMahon; W C Drevets
Journal:  Mol Psychiatry       Date:  2010-03-30       Impact factor: 15.992

9.  Expression profiling of a genetic animal model of depression reveals novel molecular pathways underlying depressive-like behaviours.

Authors:  Ekaterini Blaveri; Fiona Kelly; Alessandra Mallei; Kriss Harris; Adam Taylor; Juliet Reid; Maria Razzoli; Lucia Carboni; Chiara Piubelli; Laura Musazzi; Girogio Racagni; Aleksander Mathé; Maurizio Popoli; Enrico Domenici; Stewart Bates
Journal:  PLoS One       Date:  2010-09-07       Impact factor: 3.240

10.  Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial.

Authors:  Wayne C Drevets; Maura L Furey
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.